Amgen To Re-Submit Prolia BLA In "The Very Near Future"
This article was originally published in The Pink Sheet Daily
Executive Summary
At the J.P. Morgan Healthcare Conference, Amgen CEO Kevin Sharer said the development of REMS and post-approval safety surveillance has been holding the company up.
You may also be interested in...
Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists
Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.
Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists
Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.
Aranesp Sales Continue To Slide But Amgen Reports A Solid Year
During its fourth-quarter 2009 earnings call, Amgen also reported it has re-filed denosumab for osteoporosis with FDA.